Citadel Advisors - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$377,295
-62.3%
43,719
-54.8%
0.00%
Q2 2023$1,002,056
-10.8%
96,817
-6.5%
0.00%
Q1 2023$1,123,800
-39.7%
103,576
-37.7%
0.00%
Q4 2022$1,864,159
-31.5%
166,146
-38.1%
0.00%
-100.0%
Q3 2022$2,722,000
+1058.3%
268,447
+936.2%
0.00%
Q2 2022$235,000
-36.5%
25,908
-33.1%
0.00%
Q1 2022$370,000
-20.6%
38,743
-8.3%
0.00%
Q4 2021$466,000
-81.5%
42,246
-87.6%
0.00%
Q3 2021$2,517,000
+1044.1%
340,200
+3050.0%
0.00%
Q1 2021$220,000
-90.0%
10,800
-92.7%
0.00%
-100.0%
Q3 2020$2,199,000
-38.7%
148,752
-13.0%
0.00%0.0%
Q2 2020$3,589,000
+658.8%
170,981
+735.9%
0.00%
Q1 2020$473,000
-38.3%
20,454
-30.9%
0.00%
Q4 2019$766,000
-3.6%
29,602
-39.2%
0.00%
Q2 2019$795,000
-58.6%
48,703
-42.5%
0.00%
-100.0%
Q1 2019$1,921,000
+147.9%
84,741
+179.8%
0.00%
Q4 2018$775,000
-14.8%
30,281
+8.7%
0.00%
Q3 2018$910,000
+22.5%
27,867
-15.0%
0.00%
Q2 2018$743,000
-76.3%
32,782
-61.5%
0.00%
-100.0%
Q1 2017$3,133,000
+1311.3%
85,100
+528.6%
0.00%
Q4 2015$222,000
-66.5%
13,537
-64.5%
0.00%
-100.0%
Q1 2015$662,000
-7.7%
38,111
-20.8%
0.00%0.0%
Q4 2014$717,000
+122.0%
48,092
+243.4%
0.00%
Q3 2014$323,000
-74.5%
14,003
-64.7%
0.00%
-100.0%
Q2 2014$1,266,00039,6990.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
Link Fund Solutions Ltd 5,251,349$135,459,00069.86%
Chescapmanager LLC 949,006$24,570,0003.61%
Baupost Group 9,309,168$241,014,0002.66%
Rock Springs Capital Management LP 655,200$16,963,0000.54%
Rubric Capital Management LP 173,400$4,489,0000.51%
Newtyn Management, LLC 173,300$4,487,0000.41%
NJ State Employees Deferred Compensation Plan 38,142$988,0000.17%
King Wealth Management Group 22,500$583,0000.15%
Virtus ETF Advisers LLC 29,216$756,0000.12%
JACOBS LEVY EQUITY MANAGEMENT, INC 452,615$11,718,0000.12%
View complete list of THERAVANCE BIOPHARMA INC shareholders